×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Alagille Syndrome Companies

ID: MRFR/Pharma/4863-HCR
100 Pages
Rahul Gotadki
October 2025

Alagille syndrome is a rare genetic disorder that primarily affects the liver and heart, causing a range of symptoms such as liver damage, bile duct abnormalities, and heart problems.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Alagille Syndrome Market

Alagille Syndrome Market

 


Latest Alagille Syndrome Companies Updates:


CANbridge Pharma secures marketing approval for LIVMARLI in Hong Kong: This September 2023 approval marks a significant step towards broader access to the medication for patients with Alagille Syndrome in the region.


Patient advocacy groups like the Alagille Syndrome Alliance and Chiari & Associates for Alagille Syndrome (CAFAS) play a vital role in raising awareness, providing support and resources, and funding research for improved diagnosis, treatment, and cure for Alagille Syndrome.


Online communities and forums offer valuable information and connection for individuals living with Alagille Syndrome and their families.


List of Alagille Syndrome Key companies in the market:



  • Sanofi AG

  • Teva Pharmaceutical Industries Ltd.

  • Allergen Plc

  • Lannett

  • Albireo Pharma, Inc.

  • AstraZeneca Plc

  • Novartis AG

  • Pfizer, Inc.

  • Shire

  • Bristol-Myers Squibb Company

  • GlaxoSmithKline Plc